Year Founded
2001
Ownership
Private
Employees
~543
Therapeutic Areas
OncologyMetabolic DisordersEndocrinologyGastroenterologyWomen's Health
Stage
Commercial
Modalities
PeptidesOligonucleotide therapeutics

Chinese Peptide Company General Information

Leading CRO/CDMO specializing in synthetic peptide production with FDA-inspected GMP facility. Provides services from early drug discovery through clinical trials to commercial manufacturing.

Contact Information

Website
Primary Industry
[ "CRO", "CDMO", "Other" ]
Corporate Office
Hangzhou, Zhejiang
China

Drug Pipeline

terlipressin
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Chinese Peptide Company's pipeline data

Book a demo

Key Partnerships

Top 10 pharmaceutical companies

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Chinese Peptide Company Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Chinese Peptide Company's complete valuation and funding history, request access »